Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Thungappa

P1.01-94 Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.10-07 Health Professional’s Perception Towards Smoking: A Cross-Sectional Study From Bangalore, India.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Safety and Efficacy of the Maximum Tolerated Dose of Givinostat in Polycythemia Vera: A Two-Part Phase Ib/Ii Study

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2020English

An Application of Reinforced Urn Processes to Determining Maximum Tolerated Dose

Statistics and Probability Letters
UncertaintyStatisticsProbability
2007English

Correction: The Impact of Non-Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Clinical Cancer Research
Cancer ResearchOncology
2012English

Epacadostat Plus Pembrolizumab Is Well Tolerated in a Phase I Trial

Cancer Discovery
Oncology
2018English

The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial

Cancer Discovery
Oncology
2018English

Dose Titration Algorithm Tuning (DTAT) Should Supersede ‘The’ Maximum Tolerated Dose (MTD) in Oncology Dose-Finding Trials

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2017English

Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2005English

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy